 SHELTON, CT ACCESSWIRE May 26, 2020 NanoViricides, Inc. NYSE American:NNVC the Company, a leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, announced today that it has raised 10.22 Million in gross proceeds from the sale of 1.4 million shares of common stock, and no warrants, at a price of 7.30 per share, in a previously announced registered direct offering the Offering. The co-Placement Agents were paid a total cash fee of 8 of the gross proceeds, plus 75,000 for reimbursement of legal fees. The net proceeds to the Company were approximately 9.327 Million, after deducting placement agent fees and other costs. 